Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction
Conferences
Anderson, C; Lin, C; Scobie, MR; Rodgers, TD; Kelley, MJ; Friedman, DR
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
September 2024
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
September 2024
Volume
24
Start / End Page
S340 / S340
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Anderson, C., Lin, C., Scobie, M. R., Rodgers, T. D., Kelley, M. J., & Friedman, D. R. (2024). Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 24, pp. S340–S340).
Anderson, Clare, Chenyu Lin, Micaela R. Scobie, Thomas D. Rodgers, Michael J. Kelley, and Daphne R. Friedman. “Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24:S340–S340, 2024.
Anderson C, Lin C, Scobie MR, Rodgers TD, Kelley MJ, Friedman DR. Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S340–S340.
Anderson, Clare, et al. “Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 24, 2024, pp. S340–S340.
Anderson C, Lin C, Scobie MR, Rodgers TD, Kelley MJ, Friedman DR. Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S340–S340.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
September 2024
Volume
24
Start / End Page
S340 / S340
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology